Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma

Podoplanin (PDPN), a small transmembrane mucin-like glycoprotein, is ectopically expressed on tumor cells. PDPN is known to be linked with several aspects of tumor malignancies in certain types of human and canine tumors. Therefore, it is considered to be a novel therapeutic target. Monoclonal antib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Satoshi Kamoto, Masahiro Shinada, Daiki Kato, Sho Yoshimoto, Namiko Ikeda, Masaya Tsuboi, Ryohei Yoshitake, Shotaro Eto, Yuko Hashimoto, Yosuke Takahashi, James Chambers, Kazuyuki Uchida, Mika K. Kaneko, Naoki Fujita, Ryohei Nishimura, Yukinari Kato, Takayuki Nakagawa
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2020-11-01
Colecção:Cells
Assuntos:
podoplanin
dog
antibody therapy
tumor
melanoma
Acesso em linha:https://www.mdpi.com/2073-4409/9/11/2529
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados